BR Biopharma, Inc. (NASDAQ:BRBI) Sees Significant Decrease in Short Interest

BR Biopharma, Inc. (NASDAQ:BRBI) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,225 shares, a decline of 65.4% from the August 15th total of 3,543 shares. Based on an average daily volume of 1,065 shares, the short-interest ratio is currently 1.2 days. Currently, 0.0% of the shares of the company are short sold.

BR Biopharma Stock Performance

Shares of BR Biopharma stock traded down $0.14 on Friday, hitting $11.22. 3,840 shares of the company’s stock were exchanged, compared to its average volume of 889. BR Biopharma has a 1 year low of $9.09 and a 1 year high of $67.01. The company has a 50-day simple moving average of $10.82 and a 200-day simple moving average of $12.76. The stock has a market capitalization of $132.52 million and a PE ratio of 140.26.

BR Biopharma (NASDAQ:BRBI) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 EPS for the quarter. The company had revenue of $25.13 million during the quarter.

BR Biopharma Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Monday, August 17th were paid a dividend of $0.1415 per share. The ex-dividend date was Monday, August 17th. This represents a $0.57 dividend on an annualized basis and a dividend yield of 5.0%. BR Biopharma’s payout ratio is 512.50%.

Institutional Investors Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC purchased a new position in BR Biopharma, Inc. (NASDAQ:BRBI) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th biggest position.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BR Biopharma in a report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, BR Biopharma currently has a consensus rating of “Sell”.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.